Document is current
Any future updates will be listed below
-
Authors
Idilman, Ramazan
Razavi, Homie
Robbins-Scott, Sarah
Akarca, Ulus Salih
Örmeci, Necati
Kaymakoglu, Sabahattin
Aygen, Bilgehan
Tozun, Nurdan
Güner, Rahmet
Bodur, Hurrem
Lazarus, Jeffrey V. https://orcid.org/0000-0001-9618-2299
-
Funding
Funding for this research was provided by:
Gilead Sciences (-)
- License Information
-
More Information
Article History
Received: 6 May 2019
Accepted: 21 February 2020
First Online: 24 March 2020
Ethics approval and consent to participate
: No ethical clearance or informed consent was required as per the IRB of the Hospital Clínic, Barcelona, Spain, regulations.
: Not applicable.
: JVL has received research grants and speaker fees from AbbVie, Gilead Sciences and MSD as well as speaker fees from CEPHEID and Janssen. HR reports grants from CDC Foundation, John Martin Foundation, ASTHO, Zeshan Foundation, and other Private donors. In addition, his organization has received funding from Gilead Sciences, AbbVie, Intercept Pharma, and Vaccine Impact Modeling Consortium. He is the managing director of Center for Disease Analysis and Center for Disease Analysis Foundation. SR works at the Center for Disease Analysis, which has received funding from Gilead Sciences, AbbVie, Intercept Pharma, and Vaccine Impact Modeling Consortium. All other authors have no conflicts of interest to report.
